US equities
|
TSLA
$393.62
▲+5.75%
MU
$910.67
▲+3.77%
NVDA
$216.44
▲+2.60%
SPCX
$148.05
▲+0.38%
META
$634.53
▼-1.26%
AAPL
$344.27
▼-0.99%
SNDK
$1,262.60
▲+1.98%
INTC
$91.38
▲+5.08%
TSLA
$393.62
▲+5.75%
MU
$910.67
▲+3.77%
NVDA
$216.44
▲+2.60%
SPCX
$148.05
▲+0.38%
META
$634.53
▼-1.26%
AAPL
$344.27
▼-0.99%
SNDK
$1,262.60
▲+1.98%
INTC
$91.38
▲+5.08%
FinancialContent
Sign in
Markets
Overview
News
World markets
Treasuries
Currencies
Commodities
Economy
Stocks
Overview
Most active
Gainers
Losers
Largest companies
52-week gainers
52-week losers
ETFs
Overview
Popular funds
Most active
Gainers
Losers
News
Research
Search
Sectors
Tools
My watchlist
My portfolio
Recent quotes
Lexicon Pharmaceuticals, Inc. - Common Stock
(NQ:
LXRX
)
1.475
+0.055 (+3.87%)
Delayed Quote
Updated: 3:37 PM EDT, Oct 26, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Lexicon Pharmaceuticals, Inc. - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
Next >
Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic Cardiomyopathy
October 23, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular Disease
October 21, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Why Lexicon Pharmaceuticals Stock Popped by Almost 6% Today
↗
September 28, 2026
An analyst at a prominent research firm initiated coverage of the
Via
The Motley Fool
Lexicon Completes SONATA-HCM Enrollment, Eyes 2027 Sotagliflozin Data
↗
September 20, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) said it has completed enrollment in its Phase III SONATA-HCM study of sotagliflozin in hypertrophic cardiomyopathy, with topline data expected in the first quarter...
Via
MarketBeat
Lexicon Pharmaceuticals (NASDAQ:LXRX) Falls as Q2 Revenue Misses Estimates
↗
August 06, 2026
Via
Chartmill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Scores Perfect 10 Technical Rating After 119% Rally
↗
July 08, 2026
Via
Chartmill
Lexicon Pharmaceuticals (NASDAQ:LXRX) Q1 2026 Results Show Revenue Beat and Narrowed Loss
↗
May 07, 2026
Via
Chartmill
Lexicon Pharmaceuticals Inc. (NASDAQ:LXRX) Beats Q4 Estimates and Strengthens Cash Runway
↗
March 05, 2026
Via
Chartmill
Lexicon Pharmaceuticals to Participate at Three Upcoming Investor Conferences
September 01, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Announces New Post Hoc SOLOIST-WHF Analysis Demonstrating Consistent Sotagliflozin Results Across Baseline Blood Pressure Levels in Patients with Recent Worsening Heart Failure
August 31, 2026
Findings presented at ESC Congress 2026 and simultaneously published in JACC: Heart Failure
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Earns Third $10 Million Milestone Payment from Novo Nordisk Following Achievement of Key Phase 1 Development Milestone for LX9851
August 24, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon (LXRX) Q2 2026 Earnings Call Transcript
↗
August 13, 2026
SONATA-HCM Phase III enrollment topped 500 patients; data due Q1 2027.
Via
The Motley Fool
Topics
Earnings
Lexicon Pharmaceuticals Q2 Earnings Call Highlights
↗
August 06, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) reported a wider second-quarter loss as revenue declined sharply from the prior-year period, while the company highlighted completed enrollment in its Phase III...
Via
MarketBeat
Topics
Earnings
Lexicon Pharmaceuticals Reports Second Quarter 2026 Financial Results and Provides Clinical Updates
August 06, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Report Second Quarter 2026 Financial Results on August 6, 2026
July 30, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Completes Enrollment of Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Non-Obstructive and Obstructive Hypertrophic Cardiomyopathy (HCM)
July 27, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals vs. Pfizer: Which Drugmaker Stock Is a Better Buy in 2026?
↗
June 11, 2026
One company posts rapid revenue growth but remains unprofitable, while the other boasts global scale and steady cash flow. See how their fundamentals stack up.
Via
The Motley Fool
Lexicon to Present Data at the American Diabetes Association (ADA) 2026 Scientific Sessions
June 03, 2026
Presentations highlight consistent A1c reductions with sotagliflozin in type 1 diabetes and pharmacokinetics of pilavapadin across renal function groups
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon (LXRX) Q1 2026 Earnings Transcript
↗
June 01, 2026
Lexicon (LXRX) Q1 2026 Earnings Transcript
Via
The Motley Fool
Lexicon Pharmaceuticals to Present at the 2026 Jefferies Global Healthcare Conference
May 28, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Present at the 4th Annual H.C. Wainwright BioConnect Investor Conference
May 12, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Q1 Earnings Call Highlights
↗
May 08, 2026
Lexicon Pharmaceuticals (NASDAQ:LXRX) executives highlighted progress across late-stage regulatory programs and efforts to bolster the company’s financial position during the company’s first-quarter...
Via
MarketBeat
Topics
Earnings
Lexicon Pharmaceuticals Reports First Quarter 2026 Financial Results and Provides Clinical Updates
May 07, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals Announces $100 Million Loan Facility with Hercules Capital
May 04, 2026
$55 million funded at closing to repay existing loan facility
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals to Report First Quarter 2026 Financial Results on May 7, 2026
April 30, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon to Present Data at the American Academy of Neurology (AAN) Annual Meeting
April 17, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Announces Three Presentations at the American College of Cardiology (ACC) Annual Scientific Session & Expo
March 24, 2026
Additional analyses from the SCORED and SOTA-P-CARDIA studies provide further evidence of benefits across patient subgroups potentially related to sotagliflozin's mechanism of action
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon Pharmaceuticals and Novo Nordisk Announce initiation of Phase 1 study with oral obesity drug candidate LX9851
March 23, 2026
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon to Present Data on Effect of Kidney Function on the Long-term Efficacy and Safety of Sotagliflozin in Patients with Type 1 Diabetes at 19th International Conference on Advanced Technologies & Treatments for Diabetes
March 11, 2026
Post hoc data analysis concluded that sotagliflozin, a dual SGLT1 and SGLT2 inhibitor, improved glycemic control after one year in patients with normal and mildly reduced kidney function
From
Lexicon Pharmaceuticals, Inc.
Via
GlobeNewswire
Lexicon (LXRX) Q4 2025 Earnings Call Transcript
↗
March 05, 2026
Lexicon (LXRX) Q4 2025 Earnings Call Transcript
Via
The Motley Fool
Topics
Earnings
< Previous
1
2
3
4
5
6
7
8
9
Next >
